The Venture Codex Logo

The Venture Codex

Viscofan

Calle del Polígono Industrial Berroa, nº15 - 4ª planta, Tajonar, Navarra, 31192, Spain

Overview

Viscofan manufactures casings for the meat industry. Their products include cellulose, collagen, fibrous, functional solutions, plastics, visco fan veggie, fan, edileaf products. They use technology for all categories of casing products like cellulose, collagen, fibrous and plastic.

Total investments
6
Lead investments
2
Investments · 12mo
1
Active investors
2

Sector focus

  • Food and Beverage
  • Food Processing
  • Manufacturing
Visit website

Investment portfolio

  • BZERO

    Participated · Seed · Jul 2026

    BZERO (BZERO Materials) develops the world’s thinnest high-strength home-compostable film aimed at packaging applications. The company is based in Valencia and has attracted both financial investors and strategic agri-food partners. With the recent €1.5 million seed round, total funding raised has reached €2.5 million. New strategic participation from Viscofan and existing backers like Ship2B Ventures, CTL Investments LLC, and Torribas S.A. signal industry interest and potential for industrial collaboration. BZERO intends to use the funds to scale production and accelerate commercial adoption of its compostable film. The financing mix is positioned to combine capital with industrial expertise to speed market entry.

  • MOA

    Participated · Series A · Jun 2024

    MOA Foodtech integrates industrial biotechnology and artificial intelligence to develop high-value food ingredients from agricultural byproducts via a patented fermentation process. It converts substrates such as cereals, bagasse and legumes into competitive, low‑carbon functional ingredients that can be reintroduced into the food system. The company uses its AI platform, Albatros, to accelerate ingredient creation while reducing time and costs. Proceeds from the recent financing are intended to scale operations, expand production and commercialisation, and further develop the Albatros platform for international market launches. Founded in 2021 in Pamplona (Navarra), MOA employs 15 technical staff, 11 of whom are women. The company frames its approach as a circular solution that helps mitigate greenhouse gas emissions, deforestation and biodiversity loss by valorising large volumes of secondary agro‑food flows. MOA Foodtech is an agroalimentaria startup that develops protein ingredients of high nutritional value from agro‑food subproducts. Founded in 2020 and based at the CEIN incubator in Noain (Pamplona‑Iruña), the company is led by scientific director Susana Sánchez, CEO Bosco Emparanza and CFO José María Elorza. The startup aims to address growing demand for alternative proteins and has participated in acceleration programs such as Spain Foodtech and Orizont’s Match Point VI. MOA plans to have its first product on the market in 2022 and to grow its headcount from five employees to fourteen. The company has early commercial ties with Sanygran and Iberfruta, with options for minimum contracts of €25,000.

  • Inmedical Therapeutics

    Participated · Equity · Jan 2024

    Inmedical Therapeutics closed a first funding round of €800,000 with participation from Viscofan and Basque FCR (managed by Gestión de Capital Riesgo del País Vasco - Grupo Spri). The operation was led and advised by Elkargi, which handled analysis, valuation, structure, investor search, and negotiation of terms. Founded in 2020 and formed by four companies including I+Med, the Vitoria-Gasteiz–based startup is developing a medical device product referred to in the article as Covergel/Convergel to reduce complications in therapeutic endoscopies. Convergel is described as an easy-to-use, cost-effective bioadhesive regenerative platform that covers resection sites to prevent delayed bleeding and perforation while accelerating mucosal healing; the technology is transformable toward other medical solutions. The company has completed preclinical studies and has initiated clinical trials at several hospitals in the Basque Country, with a plan to begin commercialization in 2025 if results are positive.

  • Cocoon Bioscience

    Participated · Equity · Nov 2023

    Cocoon Bioscience develops and manufactures specialized enzymes and high-performance growth factors for pharmaceutical, biological-sciences and alternative-protein industries. Its CrisBio® technology automates insect chrysalis systems, using live insects as natural bioreactors to produce enzymes for mRNA synthesis and genetic sequencing and growth factors for cultivated meat at lower cost than other protein-expression platforms. The company says its development significantly reduces production costs and enables industrialization of these biotechnologies. Cocoon offers bespoke, on-demand protein production services and aims to be a long-term partner as customers scale processes and products. Due to strong customer demand, the firm plans to build a new, more efficient manufacturing plant at Parque Tecnológico de Bizkaia in Zamudio to scale CrisBio® to kilogram-per-year production. Proceeds from the financing will be used to expand production capacity, invest in product and process innovation, and strengthen the company. Cocoon Bioscience, born from the split of Algenex after its sale to Insud Pharma in 2022, develops biocomponents including specialized enzymes for mRNA synthesis and genome sequencing and high‑performance growth factors for the alternative‑protein industry. The company also supplies enzymes for the pharmaceutical market. Cocoon’s products target emerging global markets with significant potential. The €15M funding will be used to rapidly scale Cocoon’s platform to industrial levels. Cocoon plans a new production plant in Zamudio (Vizcaya), and when that facility is at full capacity in two to three years the company anticipates revenues of up to €80 million. The financing is intended to accelerate industrialization and commercialization of its enzyme and growth‑factor portfolio.

  • InsektLabel Biotech

    Led · Equity · Jul 2022

    Insekt Label Biotech develops ingredients derived from insects for human and functional food applications. The company operates a pilot production farm and an in-house laboratory located at BIC Bizkaia. Founded in 2019, it aims to position insect-derived ingredients as a sustainable alternative within the agro-food chain. Recent funding is being used to expand production and transformation capacity and to seek homologation of product lines under development. The company plans to digitalize and optimize critical parts of its production process, accelerate and professionalize its commercial strategy and market entry, and strengthen the team with new profiles. Insekt Label emphasizes insects' high protein yield, nutritional content and role in circular economy as core advantages for sustainable food systems.

Team

  • Juan Ignacio Villegas Díaz

    CEO

  • Iñaki Recalde

    Director of Diversification and Technology

    LinkedIn